NCT03855189View on ClinicalTrials.gov

Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)

PHASE3CompletedINTERVENTIONAL
Enrollment

345

Participants

Timeline

Start Date

August 23, 1993

Primary Completion Date

October 8, 1993

Study Completion Date

October 22, 1993

Conditions
Seasonal Allergic Rhinitis
Interventions
DRUG

Mometasone Furoate (MF)

Mometasone furoate nasal spray administered as 200 mcg total dose per day for 4 weeks.

DRUG

Beclomethasone Dipropionate (BDP)

Beclomethasone dipropionate nasal spray administered as 168 mcg twice daily (BID) \[336 mcg total dose per day\] for 4 weeks.

DRUG

Placebo

Placebo nasal spray administered for 4 weeks.

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT03855189 - Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013) | Biotech Hunter | Biotech Hunter